The present study was the first report clearly demonstrating the striking different mechanisms in anticancer immunity between TAA peptide-based vaccines such as WT1 peptide vaccine and immune checkpoint inhibitors such as anti-PD-1 antibody for the same tumor under the same microenvironment. Here, WT1 is linked to neoplasm.